Skip to content

Cariprazine

SGA • Last reviewed 2025-09-23

Brands: Vraylar

Sources updated 2025 • 1 references

Summary

General Information

Indicated for: Schizophrenia; manic/mixed and depressive episodes (bipolar I); adjunct to antidepressants for MDD. Second‑generation antipsychotic (SGA)

Dosage & Administration

Typical dose range: 1.5–6 mg/day

Indications (label)

Schizophrenia; manic/mixed and depressive episodes (bipolar I); adjunct to antidepressants for MDD.

View labelExact

Mechanism (brief)

D3/D2 partial agonist (D3‑preferring); 5‑HT1A partial agonist; 5‑HT2A antagonist.

Metabolism & Half‑life

  • Metabolism: CYP3A4; active metabolites with long half‑lives.
  • Half‑life: Long effective half‑life due to metabolites (days).

Therapeutic Drug Monitoring (TDM)

Recommended: No

References